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Abstract 
Introduction: Anti-seizure medications (ASMs) are commonly used to prevent 
recurring epileptic seizures, but around a third of people with epilepsy fail to achieve 
an adequate response. Vagus nerve stimulation (VNS) is clinically recommended for 
people with drug-resistant epilepsy (DRE) who are not suitable for surgery, but the 
cost-effectiveness of the intervention has not recently been evaluated. The study 
objective is to estimate costs and quality-adjusted life years (QALYs) associated with 
using VNS as an adjunct to ongoing ASM therapy, compared to the strategy of using 
only ASMs in the treatment of people with DRE, from an English National Health 
Service perspective. 
Methods: A cohort state transition model was developed in Microsoft Excel® to model 
costs and QALYs of the VNS+ASM and ASM only strategies. Patients could transition 
between five health states, using a 3-month cycle length. Health states were defined 
by an expected percentage reduction in seizure frequency, derived from randomised 
control trial data. Costs included the VNS device as well as its installation, setup, and 
removal; ASM therapy; adverse events associated with VNS (dyspnoea, hoarseness and 
cough); and health-state costs associated with epilepsy including hospitalizations, 
emergency department visits, neurologist visits and primary care visits.  A range of 
sensitivity analyses, including probabilistic sensitivity analysis, were run to assess the 
impact of parameter and structural uncertainty. 
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Results: In the base case, VNS+ASM had an estimated incremental cost-effectiveness 
ratio (ICER) of £17,771 per QALY gained compared to ASMs alone. The cost-effective 
ICER was driven by relative reductions in expected seizure frequency and the 
differences in health care resource use associated therewith. Sensitivity analyses found 
that the amount of resource use per epilepsy-related health state was a key driver of 
the cost component. 
Conclusions: VNS is expected to be a cost-effective intervention in the treatment of 
DRE in the English National Health Service. 
 
Keywords: Cost-effectiveness model; drug-resistant epilepsy; economic evaluation; 
epilepsy; vagus nerve stimulation; Markov model; anti-epileptic drugs 
 
JEL Codes: C60; C6; C; C02; C31; C3; I19;  I1; I 
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Plain Language summary 
People with epilepsy are usually given anti-seizure medications (called ASMs) to help 
prevent their seizures from reoccurring. However, around a third of them will keep 
having seizures even with the medication; this is called drug-resistant epilepsy (DRE). 
Treatment options for DRE include, but are not limited to, surgical or therapeutic 
device related interventions or trying alternative ASM combinations.  
In the English National Health Service (NHS), vagus nerve stimulation (VNS) therapy is 
recommended by the National Institute for Health and Care Excellence (NICE) for DRE 
patients who are still having seizures despite trying a number of different ASMs, and 
who cannot have brain surgery. Following NICE technical standards, we developed an 
economic model to test whether VNS would be a cost-effective add-on to ASM 
therapy. The model uses current costs for VNS therapy and takes a more nuanced 
approach to the longevity of the VNS device than previous research did.  
Results showed that adding VNS to ASMs can be a cost-effective way to treat DRE in 
today’s NHS in England. VNS reduces the number of seizures, which is expected to 
improve patients’ quality of life and cut NHS costs that would otherwise have been 
needed to look after patients who had a seizure (for example, emergency visits or 
inpatient hospital stays). Sensitivity analyses tested aspects of uncertainty in our 
model. These highlighted the need to further understand the relationship between 
seizures, their severity and health care usage, if we want to make improved cost-
effectiveness analyses about DRE in the future. 
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Introduction 
Epilepsy is a common and serious neurological disorder, affecting up to five million 
new people every year, with a global prevalence of approximately 50 million [1]. 
People with epilepsy can suffer from frequent and recurring seizures, varying in nature 
and severity [2]. There is a wide range of potential impacts both on the quality of life 
of patients and their caregivers [3], as well as the amount of health care resources 
required to manage the condition [1]. 
The goal of epilepsy management is to reduce the frequency of seizures, and anti-
seizure medications (ASMs) are the most common therapeutic intervention. ASM 
treatment usually starts as monotherapy and may progress to a combination of drugs 
if needed [4]. Approximately a third of people with epilepsy fail to achieve an adequate 
response to treatment with ASMs and can be described as having drug-resistant 
epilepsy (DRE) [5]. Prevalence of DRE varies according to region and the definition of 
drug resistance [6-10]. The Task Force of the International League Against Epilepsy 
(ILAE) Commission on Therapeutic Strategies defines DRE as a failure of adequate trials 
of two tolerated and appropriately chosen and used ASM schedules (whether as 
monotherapies or in combination) to achieve sustained seizure freedom [5]. People 
with DRE require more hospitalisations and emergency department visits compared to 
people whose epilepsy is successfully managed with ASMs, and their mental health 
and quality of life are significantly poorer on average [11-13]. Depressive symptoms 
have been identified in over one half of people with DRE [14] and cognitive 
impairment is a common feature [11].  
Vagus nerve stimulation (VNS) has been an important option for managing DRE for 
three decades, with approximately 125,000 patients across 85 countries having 
received the treatment since 1989 [15]. International clinical bodies recommend VNS 
as an effective and well-tolerated treatment for people with DRE whose options for 
pharmacotherapy or surgery are limited [4,16,17]. In England for example, the 
National Institute for Health and Care Excellence (NICE) recommends VNS as an 
adjunct to ASMs in treating adults, young people and children with DRE who are not 
suitable for resective surgery [4].  
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A sizable body of evidence now exists to demonstrate that VNS is clinically effective 
and several studies [18-20] have found it to be cost-effective owing to the reduction in 
seizure frequency, which consequently is expected to improve the patients’ quality of 
life and reduce downstream healthcare costs [21-23]. However, a contemporary 
analysis has not been conducted to estimate the cost-effectiveness of VNS in the 
English healthcare setting.  
The aim of this study is to evaluate the cost-effectiveness of VNS in combination with 
ASM compared to ASM alone, for the treatment of people with DRE from an English 
NHS and personal social services (PSS) perspective, according to the standard 
methodology set out by NICE for health technology appraisals. To meet this aim, our 
objective was to develop an economic model to estimate and compare the costs and 
benefits (expressed as quality-adjusted life years [QALYs]) and derive an incremental 
cost-effectiveness ratio (ICER).  
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Methods 
The Methods section provides a brief overview of the economic analysis. A full account 
of all modelling elements and considerations is provided in the Technical Supplement. 
Design and population 
This was a cost-utility analysis developed according to NICE’s technology appraisal 
guidance [24]. Costs and benefits of two DRE management strategies were estimated 
and compared: 
1. ASM regimen as typically administered in DRE management, with no VNS; 
2. VNS administered as adjunct to ASM regimen. 
Health benefits were estimated as QALYs, and costs took an English NHS and PSS 
perspective. To take into account time preference, costs and benefits were discounted 
at an annual rate of 3.5%, as specified by the NICE reference case [24]. A time horizon 
of 10 years was used to capture the most relevant costs and benefits relating to the 
treatment decision for DRE for which there is evidence to populate the model. If the 
incremental cost-effectiveness ratio (ICER) is below the acceptable threshold, the 
intervention of interest can be considered cost effective. To assess cost effectiveness 
of VNS in our analysis, the NICE cost-effectiveness threshold range of £20,000 per 
QALY to £30,000 per QALY was used [24]. The likelihood of cost-effectiveness given 
alternative thresholds was also calculated and is presented as a cost-effectiveness 
acceptability curve. 
Primary data on the efficacy of VNS were sourced from two randomised controlled 
trials (RCTs) (named E03 and E05) evaluating the efficacy of high versus low 
stimulation VNS therapy given adjunctively to ASM [25,26]. For the purposes of 
modelling, adjunctive low stimulation therapy was assumed to be equivalent to ASM 
therapy only. These two RCTs also informed population characteristics used for the 
model cohort, as summarized in Table 1. Both trials had a small proportion of children 
participating; these were included and adjusted for accordingly in the costing, but the 
purpose of this analysis is primarily to model costs and benefits in the adult 
population, and not to model in detail the management of DRE in children.  
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Model structure 
We developed a cohort state transition model in MS Excel (version 2016). In line with 
previous cost-effectiveness analyses in this therapy area [30,31], health states were 
defined by percentage reductions in seizure frequency achieved from baseline:  
 100% reduction (seizure-free); 
 75-99% reduction (responder); 
 50-74% reduction (responder); 
 less than 50% reduction (no response). 
Death was also modelled. Cycle length was set to 3 months, to correspond with the 
study durations of trials E03 and E05. Model structure is shown in Figure 1 and Figure 
2.  
By default, all patients started in the ‘no response’ health state. VNS patients were 
able to transition between health states any time up to 24 months post-implantation, 
after which their health state was assumed to remain fixed (subject to death or 
discontinuation). ASM patients could move between health states in the first 3-month 
cycle, and thereafter their response category was assumed to remain static. Costs 
(other than the initial VNS implantation) and outcomes were half-cycle corrected. 
VNS patients could discontinue treatment due to explantation at any point or due to 
inadequate response at 24 months, at which point the device was assumed to be 
deactivated. In both cases, patients would revert to the health-related quality of life 
(HRQoL) and costs of ASM patients in the ‘no response’ health state. Deactivation does 
not require an invasive procedure or additional cost to a routine care appointment, 
and is essentially a continuance of VNS implantation without associated benefits or 
risks of VNS treatment (with the exception of explanation to remove the device later if 
required).   
The likelihood of explantation and battery replacement were modelled over time using 
real-world data and fitted parametric curves (see Discontinuation).  
Figure 1. Model structure - treatment with VNS and ASM 
Please use Figure1_600DPI.JPG 
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Abbreviations: ASM, anti-seizure medication; DRE, drug-resistant epilepsy; VNS, vagus nerve 
stimulation. 
Figure 2. Model structure - treatment with ASM alone 
Please use Figure2_600DPI.JPG 
Abbreviations: ASM, anti-seizure medication; DRE, drug-resistant epilepsy; VNS, vagus nerve 
stimulation. 
Clinical evidence inputs 
Format 
Input parameters were calculated as means. Upper and lower limits for the 
deterministic sensitivity analysis (DSA) were derived from reported statistics in the 
source material unless otherwise indicated in the tables. 
Efficacy and health state transitions  
For VNS patients, individual level patient data (IPD) from the E03 and E05 [27] studies 
were used to inform effectiveness estimates (expressed as a relative percentage 
improvement in seizure frequency between VNS and control arm) over the first three 
months of the model. Longer-term effectiveness of VNS was informed by the relative 
increase in ‘responder’ and ‘seizure free’ patients from a systematic review of long-
term outcomes in VNS-treated patients, carried out by Englot et al (2016) [32]. The 
systematic review found that patients’ response to VNS, and movement toward 
freedom from seizures, continued over a 2-year period after initiation of VNS and the 
response rate was sustained thereafter until at least 4 years [32]. This trend was 
further supported by a real-world registry analysis also conducted by Englot et al. in 
their 2016 publication [32], as well as an open-label, long-term efficacy study of VNS 
patients enrolled in the E01-E05 trials conducted by Morris et al. [16].  
For the DRE patient cohort treated with ASMs only, their prior established non-
response to epilepsy medication could lead one to assume that overall, their therapy 
will yield a reduced response over time. However, because there is limited evidence to 
model the longer-term response for DRE ASM patients, our model took a conservative 
assumption that ASM patients would maintain the same level of response and seizure 
frequency observed in the “low stimulation” arm patients at the end of the E03 and 
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E05 trial period at 3 months. Applied to the model, this meant that despite having drug 
resistance, around 16% of ASM patients remained in “responder” health states 
throughout the model time horizon.  
Transition probabilities developed based on clinical evidence are summarised in Table 
2. Sensitivity analyses were undertaken to test the impact of a reduced treatment 
effect of VNS in the longer term as well as an increased return to the “no response” 
state for ASM patients.  
Adverse events 
Only adverse events associated with VNS were considered in the model. Three adverse 
events identified as commonly observed in VNS clinical trials [33] were included as 
shown in Table 3. Per-cycle adverse event probability was informed by 1, 2, and 3+ 
year incidence rates reported in Morris et al. [33]. Other events, such as cognitive 
effects associated with ASMs [34], were not modelled as the base case assumed both 
cohorts, whether on VNS or not, would continue to receive the same stable ASM 
regimens throughout the time horizon. 
The most common complication of VNS implantation is surgical site infection [35]. The 
observed wound infection rate post implantation is 1.3% [36]. The cost of treating 
infection was not modelled separately, since the NHS reference cost used for VNS-
related procedures covers the potential costs of recovery, infection management and 
other related issues. Surgical site infection was considered to have a transient, and 
therefore minimal, impact on HRQoL across the time horizon.  
Discontinuation of therapy or replacement due to battery depletion 
Patients receiving VNS could discontinue treatment due to non-response to therapy 
(leading to the deactivation of the device) or if their device had to be explanted, with 
the latter involving an additional cost of an explantation procedure. Replacement of 
the VNS device due to battery depletion is associated with a respective cost, however, 
patients continued to benefit from VNS in terms of their health status.  
Real-world registered implant data from the United States (US), detailing the use of 
VNS (Aspire SR 106) in 24,686 patients for up to 7 years, were used to generate 
Ac
ce
pt
ed
 M
an
u
cr
ipt
 
Kaplan-Meier data regarding explanation and replacement probabilities (data on file, 
provided by LivaNova) [15].  
A range of curve functions based on these data was tested and assessed for goodness 
of fit, with generalised gamma and Gompertz functions selected for explantation and 
replacement respectively (see Figure 3 and Figure 4). Full details of the extrapolation 
and goodness-of-fit assessment statistics are provided in the Technical Supplement. To 
test the lower and upper bounds of uncertainty in deterministic sensitivity analysis, the 
lower and upper 95% confidence interval for the coefficients feeding into the 
extrapolation were used. 
Figure 3. Extrapolation function - time to VNS device explantation  
Please use Figure3_600DPI.JPG 
 
Figure 4. Extrapolation function - time to VNS device replacement 
Please use Figure4_600DPI.JPG 
 
Drug reductions 
Observational studies suggest that successful VNS treatment can alleviate the need for 
ASM use in the long term [37,38]. This potential benefit was not modelled in the base 
case, since the E03 and E05 trial protocols did not stipulate ASM dose reductions. 
However, a study by Tatum et al. [37] observed 48% of VNS patients had a reduction in 
ASM dosage compared to 10% in the control group, with a mean change in ASM use 
per VNS patient of -0.43 (reflecting approximately a 15% reduction in use from 
baseline). To explore the impact on the ICER, a threshold analysis was designed which 
modelled a range of ASM dose reduction levels for a selection of typical ASM 
regimens.    
Health related quality of life  
A utility score for each health state was obtained using data from a prospective study 
of 81 patients by Messori et al. [22], which estimated time trade-off utilities for a set of 
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seizure frequency categories. These categories, which reflected absolute numbers of 
seizures, could be mapped with reasonable similarity onto the percentage seizure 
reduction categories in E03 and E05. Messori et al. was selected as the evidence 
source over other studies [23,39], because it used the NICE-preferred method for 
estimating utilities and had a distribution of seizure frequencies which most closely 
resembled E03 and E05 study populations. 
To derive utilities for each health state, we calculated the relative difference between 
utilities for lower response states and the ‘seizure free’ health state (which was 
assumed initially to be equal to the English general population [29]). We then applied 
these relative differences to a baseline population value (0.92), which had been 
adjusted for the mean age and gender mix of the model population per the Ara and 
Brazier method [29]. The resulting utility values were used for each health state. Utility 
values used to derive health state utilities are shown in Table 4. The baseline value was 
adjusted for cohort mean age at each cycle, meaning all health state utilities remained 
age- and gender-adjusted throughout the time horizon. 
The three types of VNS adverse events were modelled to have disutility, estimates of 
which were obtained from two published studies as shown in Table 5. Although the 
studies captured disutility associated with dyspnoea, cough and hoarseness, they were 
not carried out in DRE patient populations. 
Costs and resource use 
Health state costs  
Healthcare resource unit costs, summarized in Table 6, were obtained from publicly 
available sources, in line with NICE health technology assessment methodology. 
General practitioner costs were taken from the latest Personal Social Services Research 
Unit Costs of Health and Social Care report [42]. Secondary care costs for hospital 
admissions, neurologist visits or VNS procedures were sourced using the most recent 
listing of NHS reference costs at the time of writing [43]. Because costs for people with 
DRE were not available, it should be noted that the costs for hospital admissions were 
sourced for people with nerve disorders, epilepsy or head injury, with the derived unit 
cost weighted for the associated activity by comorbidity score. In the sensitivity 
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analysis, the cost of inpatient care is varied in line with level of expected comorbidity 
(more detail can be found below and within the Technical Supplement). 
Health care resource assumptions 
The rate at which the above healthcare resources were used in each health state was 
sourced from available literature and summarised as annual values in Table 7. These 
frequencies were multiplied by unit costs to give annual costs as shown in Table 8. 
Resource use reported for VNS patients in an English setting 3 years post-implantation 
was used for the 50-74% health state [34]. No data on the resource use of DRE patients 
who achieved a 75-99% reduction in seizures were identified. It was assumed that the 
relative decrease of 15% in the mean seizure frequency of patients achieving a 50-74% 
and 75-99% seizure reduction in the E03 and E05 clinical trials would correspond to an 
equivalent relative decrease in resource use between these health states. In the 
absence of a UK study, the lower bounds of the incidence rate ratios of “well-
controlled” versus “uncontrolled” epilepsy in the US [21] were applied to the 75-99% 
health state to derive resource use for the <50% health state. English guidelines 
recommend that people with epilepsy should have a regular structured review, which 
may be carried out by a specialist depending on the person’s wishes, circumstances 
and epilepsy [4]. The guidance also recommends specialist referral for management of 
refractory epilepsy [4]. On this basis, it was assumed a typical patient with DRE would 
have 1.5 annual outpatient visits if they were seizure free. It was also assumed that 
10% of the annual outpatient visits for patients in any health state would require an 
additional GP visit, in addition to an assumed 0.01 probability of a GP visit per seizure. 
This approach to primary care resource estimation is in line with a previous cost-utility 
study in refractory epilepsy [31].  
Anti-seizure medication costs 
No direct evidence on the schedules of ASMs administered to DRE patients was 
identified for the English context, with important epilepsy studies not reporting on the 
regimen for DRE patients specifically [44-46]. Studies E03 and E05 did not capture 
specific ASM prescription details; they are also several decades old meaning they are 
neither sufficiently detailed nor current to inform a contemporary analysis. 
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As an alternative, a weighted average quarterly cost of £683 per patient, based on an 
assumed basket of three ASMs, was applied in both groups. The percentage mix of 
specific drugs within this schedule was informed by the NHS Prescription Cost Analysis 
(PCA) database [47]; unit costs and typical doses were sourced from the National Drug 
Tariff and the British National Formulary (BNF) [48]. The derivation of the ASM cost is 
provided in the Technical Supplement. 
The combined impact of ASM dose reduction for VNS patients, together with using 
specific, alternative regimens of multiple ASMs, was explored in a scenario analysis.  
VNS costs – implantation, explantation and battery replacement 
An overview of the values used to estimate the cost of VNS implantation, as well as its 
explantation and replacement where applicable, is given in Table 9. The costs of VNS 
implantation, explantation and replacement includes additional neurologist visits for 
VNS interrogation and programming.  
Adverse event costs 
Table 10 details the expected resource use and associated cost for a patient 
experiencing one adverse event over the course of one year. The mean cost per cycle 
was estimated and applied proportionally to the percentage of the cohort 
experiencing the event in any given three-month cycle.  
Sensitivity and scenario analyses 
Deterministic sensitivity analysis 
This was undertaken to identify the key drivers of model outcomes by varying single 
parameters, or groups thereof as appropriate by a plausible minimum and maximum 
range reported from the source, or where this was unavailable by ±15%, keeping all 
other inputs constant. 
PSA 
Parameter uncertainty was assessed by probabilistic sensitivity analysis (PSA), using 
5,000 simulations and the likelihood of being cost-effectiveness at various thresholds 
evaluated. The parameter distributions used in PSA are provided in the Technical 
Supplement.  
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Other sensitivity analyses 
A set of threshold and scenario analyses was designed to test the model’s sensitivity to 
the following concepts: 
 mapping healthcare resource use to health states; 
 assumptions regarding longer-term treatment effect; 
 reducing ASM use whilst on VNS, testing a range of alternative ASM regimens; 
 expected inpatient and elective cost burden for a DRE patient, with various 
levels of comorbidity and complexity. 
Scenario analyses and their results are reported in detail in the Technical Supplement. 
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Results 
Base case 
The cost-effectiveness analysis estimated an incremental total cost of £8,430 and an 
incremental QALY gain of 0.476 for VNS + ASM versus ASM alone. The ICER was 
£17,711 per QALY gained, suggesting that VNS is a cost-effective treatment option in 
the English healthcare setting. Detailed results are shown in Table 11. 
Sensitivity analysis 
Of all the deterministic sensitivity analyses undertaken (see Table 12 and Figure 5), 
only the input of extreme values for explantation probability and inpatient unit costs 
resulted in a cost-ineffective ICER relative to NICE thresholds of £20,000 to £30,000 per 
QALY gained.  
The ICER remained under the £30,000 threshold in all sensitivity analyses that tested a 
15 percent variation in the overall costs of implant, replacement and explant, 
respectively. Including costs for additional follow up neurologist visits for programming 
or increased cost of treatment of adverse events is not expected to change conclusions 
of the analysis. 
Figure 5. Tornado diagram 
Please use Figure5_600DPI.JPG 
Abbreviations: A&E, hospital accident & emergency department; ASM, anti-seizure medication; GP, general 
practitioner; NMB, net monetary benefit; QALY, quality adjusted life year; SMR, standardized mortality ratio; TRAE, 
treatment-related adverse event; VNS, vagus nerve stimulation. Notes: Where a parameter sensitivity analysis 
involved change to a single value, lower and upper bound values are shown on the diagram; *applied for the cost of 
the procedure related aspect of implant and replacement; ¥ lower or upper bound applied to the group of inputs 
informing the parameter simultaneously. 
Probabilistic sensitivity analysis 
In the probabilistic sensitivity analysis, VNS was dominant (more effective and less 
costly) in 3.48% of the 5000 iterations, with a probabilistic incremental net monetary 
benefit of £843 (95% CI: -£8,415 to £11,508). VNS was likely to be cost-effective at the 
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£20,000 threshold in 55% of iterations and at the £30,000 threshold in 84% of 
iterations. PSA scatterplot and cost-effectiveness acceptability curves are shown in 
Figure 6. 
Figure 6. Probabilistic sensitivity analysis - scatter plot and cost-effectiveness acceptability curve 
Please use Figure6_600DPI.JPG 
Scenario analyses 
Mapping healthcare resource use to health states  
Because of the uncertainty associated with mapping healthcare resource use to seizure 
reduction health states, a set of scenario analyses, provided in the Technical 
Supplement, was run to test the various assumptions required in this mapping. It was 
apparent that the cost-effectiveness results are sensitive to different healthcare 
resource use assumptions. If future research indicates a different ratio of health care 
resource utilisation between health states, then conclusions of the analysis could 
change. 
Assumptions regarding longer-term treatment effect  
A range of analyses which varied either the amount or duration of VNS effect, or the 
duration of patient response to treatment, showed that the ICER was robust to a wide 
range of uncertainty around its real-world and longer-term effectiveness (inclusive of a 
reduction in treatment effect) remaining below £30,000/QALY in all tested scenarios. 
Reducing ASM use whilst on VNS, testing alternative ASM regimens 
This analysis illustrated that if VNS patients have a reduction in their ASM 
consumption, the cost-effectiveness of VNS improves. For example, if the reduction in 
ASM use reported by Tatum et al. [37] is modelled using the base-case bundle of 
ASMs, the ICER reduces to £13,364. 
In the base case, the approximated cost of a bundle of ASMs is inconsequential to the 
incremental results because VNS was not assumed to affect ASM consumption. 
However, to obtain a more detailed overview of scenarios where VNS patients are able 
to reduce their ASM use, we undertook analyses testing a series of costs of ASM 
combinations believed to be typically trialled by people with DRE, alongside 
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hypothetical percentage reductions in ASM use. The higher the cost of the ASM bundle 
which the patient starts with, the more sensitive the percentage reduction in ASM use 
becomes and the more cost-effective VNS, as shown in the Technical Supplement. 
Expected inpatient and elective cost burden for a DRE patient  
As the cost of inpatient care associated with health states was found to be a key driver 
in the cost-effectiveness analysis, a further two-way sensitivity analysis was conducted 
whereby costs derived for groups of increasing comorbidity (defined by the HRG 
complications and comorbidity [CC] score) were examined. For example, VNS was 
expected to be dominant (more effective and cost saving) if the costs associated with a 
CC score above 9 were applied for hospitalisation. Only when costs were at the 
minimum value for non-elective care (i.e. for a short stay of a patient with a CC score 
of 0-2) was VNS found to be not cost-effective (full table in Technical Supplement). 
The cost associated with the procedure of implant, explant and replacement  
The base-case analysis used the combined cost for the VNS device and the all-
absorptive NHS reference cost to estimate the surgical costs of the procedure 
involved.   However, as the scenario analysis revealed, substituting the NHS reference 
cost of the procedure with that of the NHS tariff (which should represent catch-all cost 
items that trusts can charge for VNS procedures) resulted in a markedly lower ICER of 
£5,766. 
  
Ac
ce
pt
ed
 M
an
us
cr
ipt
 
Discussion 
Overview and context 
This economic model provides a comprehensive case, that uses contemporary 
estimates of cost, replacement and explantation events, for the cost-effectiveness of 
VNS in the treatment of DRE in the English NHS, with a base-case ICER of £17,771 per 
QALY. A few older analyses exist [19,20], but they do not use current costs, guidelines, 
or research and none utilised real-world evidence on VNS explantation or 
replacement.  
The main benefit of VNS in DRE management is that it reduces seizure frequency and 
the often-costly healthcare interventions which DRE requires. For example, the 
reduction in inpatient, outpatient and emergency care costs associated with improved 
control of epilepsy [21, 34] is expected to offset the costs of the VNS intervention 
sufficiently that VNS is considered a cost-effective treatment. Furthermore, there is a 
potential for some VNS-treated patients to be able to reduce their burden of ASM 
regimens [37] and rescue medications, which could not only save costs of the 
medication but also lead to an alleviation of medication side effects [37].  
The conclusion of cost-effectiveness, utilising the NICE threshold range, was robust to 
nearly all sensitivity analyses and only generated cost-ineffective ICERs in a minority of 
scenarios.  Firstly, a cost-ineffective ICER was generated where health care unit cost 
for hospitalisation was assumed to be unrealistically low when applied on a cohort 
basis (i.e. assuming that all DRE patients have the lowest patient complexity and 
comorbidity score and shortest reported length of stay, even though the evidence 
suggests a heterogeneous case mix inclusive of high-comorbidity patients [11,43]). 
Secondly, a cost-ineffective ICER was generated when upper confidence limits for the 
extrapolation curve coefficients were used and resulted in unrealistic estimates for the 
probability of needing explantation – in this extreme scenario, an assumed 22% of 
patients needed explantation within the first cycle and 27% needed explantation by 
the end of the time horizon. However, the Kaplan Meier data at 7.14 years (last known 
explant) suggest a probability of explantation (for any cause) of only 2% at this time 
point (see Figure 3). Finally, varying assumptions in the estimation of health state 
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resource use had potential to both increase and decrease the ICER. Further research 
regarding resource use in relation to seizure frequency would be of benefit in 
modelling this aspect more robustly. 
The choice of extrapolation function for the long-term probability of VNS device 
replacement may have underestimated the longevity of the VNS device when 
compared to what is observed in real clinical practice (see Figure 3)[15]. However, in 
this study, time to replacement did not feature as a sensitive parameter because the 
cost of expected replacement was incurred within the time horizon and only the 
timing of the cost changed. This differs from the impact of explant, whereafter 
patients returned to a ‘no response’ health state, experiencing no treatment benefit at 
all for the rest of the time horizon. Further, forcing deactivation at 24 months due to 
lack of response was a simplification made for purposes of this cohort model, whereas 
it is suspected in practice that individual non-responding patients would continue with 
an activated device beyond this point with potential to respond. 
Our model results are consistent with existing research from the UK. Forbes et al. 
(2003) reported an ICER of £28,849 per QALY for a time horizon of 5 years and a 
Scottish perspective [20]. A later update by Forbes et al. in 2008 using more recent 
data on device longevity and estimates of efficacy led to an ICER of £4,423 per QALY 
[19]. In contrast, we estimate the ICER to be in between the previously published 
estimates, noting that our study applied a more contemporary (and higher) cost for 
the VNS intervention and used real-world evidence to estimate rates of VNS 
explanation and replacement. Camp et al. (2015) found in an English setting that 
healthcare resource costs, in general, decreased over the longer term after VNS was 
implanted [34]. 
The finding that health care expenditure reduces post VNS is also supported by 
international studies. A Belgian cost-consequences analysis reported that mean annual 
direct medical costs per patient reduced from US$8,830 to US$4,215 [49]; while a 
Danish study [50] found a statistically significant cost reduction for epilepsy-related 
outpatient services, inpatient admission and prescription medicine. A small Polish 
study reported that direct medical costs continued to reduce after VNS (EUR 53,840 
versus EUR 43,120 for first and second year follow up, respectively)[51]. A US 
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retrospective 4-year analysis suggested statistically significant reductions in both 
health care utilization and time spent on health-related activities [53]. Other economic 
analyses from the US report expected net cost savings with VNS 1.5 to 1.7 years post 
VNS due to reduced resource use expenditure following the VNS procedure [52,53]. 
The complete offset of the cost of the VNS therapy in the US may be partially driven by 
the difference in resource use between uncontrolled and controlled epilepsy and high 
unit costs of care. The greater the difference between the costs of managing 
controlled versus uncontrolled epilepsy, the more cost-effective (or in the case of the 
US, cost saving) VNS is expected to be. 
The cost-effectiveness of VNS therapy has also been evaluated in the treatment of 
children with DRE from a Dutch [55,56], Jordanian [18] and US [57] perspective. 
Although findings of such studies have limited generalisability to our English and 
mostly adult population of interest, the comparison between studies from the 
developed and developing countries suggests that a driver of downstream cost-savings 
is the access to and use of high-cost health care (which may be avoided with enhanced 
seizure control). This supports our own observation that the higher the relative 
inpatient care cost burden associated with uncontrolled epilepsy, the more cost-
effective VNS is expected to be. It may be reasonable to hypothesize, therefore, that 
VNS would be of value for specific patient groups that would otherwise have seizures 
with a high-cost burden if hospitalised. 
In summary, international evidence of cost reduction, combined with the expected 
reduction in seizure frequency and, by implication, improved HRQoL [22,23,39,58] 
supports the expectation that VNS is a cost-effective intervention.  
Strengths and limitations 
The strengths of the model include its use of bespoke analyses from IPD of 310 trial 
patients to inform effectiveness estimates, and its use of extrapolation functions based 
on large-scale, long-term registry data to estimate device longevity. 
Limitations include the use of health states defined by a percentage reduction in 
seizure frequency, rather than absolute frequencies of seizures. This approach, whilst 
consistent with trials E03 and E05, as well as other published economic evaluations 
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[31,59-62], created challenges when mapping costs and utilities from various sources 
in the literature. In particular, the mapping from different sources to inform health 
state resource use introduced uncertainty into conclusions. Despite our rigorous and 
cautious approach to mapping, it remains unclear exactly how closely the true 
distribution of seizure frequency in the model population aligns with those of studies 
in the literature which we used for our estimates of healthcare resource use and 
utilities.   
The analysis utilised data specific to DRE patients wherever possible, but there is 
limited evidence about the resource utilisation and unit costs of care for people with 
DRE specifically. For the VNS cohort, resource estimates were primarily informed by 
all-cause hospital admissions (as reported by Camp et al.[34]) rather than admissions 
specifically linked to epilepsy. This was done to avoid missing hospital resource use 
which is not coded with a primary diagnosis of epilepsy but is nonetheless likely to be 
linked to poor seizure control. In this regard, it is notable that Camp et al. reported a 
decrease in resource use after VNS therapy, both for admissions coded with a primary 
diagnosis of epilepsy and for all patient admissions. The study did not report 
specifically on more expensive “intensive care” stays, and as such we may have 
underestimated cost of hospitalisation if VNS has a treatment effect on this parameter. 
Sensitivity analysis suggests that the greater the cost of the inpatient stay, the more 
cost-effective VNS is likely to be; however, granular cost and resource data specific to 
the DRE population would be required to fully understand the impact of uncertainty 
introduced by our resource and cost estimation.  
More broadly, the resource use component did not account for the cost of social care, 
despite this potentially being substancial given the needs of people with DRE and their 
carers when living and managing their condition in the community. 
A further limitation is that the trials informing efficacy did not compare VNS therapy 
against ASM therapy only. The E03 and E05 studies compared VNS at ‘high stimulation’ 
settings to a presumed sub-therapeutic ‘low stimulation’ regimen. ASMs were given in 
both arms. The observed efficacy of the ‘low stimulation’ arms from E03 and E05 
informed the estimated efficacy of the modelled ‘ASMs only’ strategy. It is possible 
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that any residual benefit of ‘low stimulation’ led to the efficacy of the modelled 
strategy of ASMs only being overestimated. Furthermore, the original trials of VNS 
used are several decades old. Therapeutic advances in VNS treatment (e.g. implant 
technology, diagnostics, imaging, surgical procedures) since the time of the trials could 
mean that the model omits potential benefits of current VNS therapy.  
Advances in ASM therapy could also be expected to reduce seizure burden when used 
in isolation or with VNS adjunctively. However, a relatively contemporary UK 
observational study concluded that that seizure freedom rates have remained virtually 
unchanged for the past two decades despite the introduction of new therapies [44]. 
Although the study notes a higher rate of seizure freedom than suggested by E03 and 
E05 trials, the incremental benefit of VNS as an adjunct to modern ASMs compared 
with the older ASMs remains unclear, due to the lack of comparative studies. Further 
research would be required to understand the impact of including newer therapies.   
Finally, the analysis conservatively assumed that seizure frequency would not impact 
on mortality and no change to cost or HRQoL would be expected if a patient 
experienced less than a 50% reduction in seizures. The omission of a mortality 
relationship may be important since sudden unexpected death in epilepsy (SUDEP) has 
been estimated to account for 38% of deaths in people with epilepsy [63]. There are 
also potentially further incremental gains in HRQoL and costs between DRE patients 
who achieve some form of response to therapy versus those who do not; this may not 
be adequately captured by the five health state model framework. For example, even 
a low percentage reduction in the frequency of severely disabling seizures could 
substantially reduce health care cost burden and improve HRQoL. 
 
Conclusions 
VNS is considered to be a cost-effective intervention as an adjunct to ASMs in people 
with DRE who are not considered suitable for surgery. The conclusion is driven by a 
demonstrated reduction in seizure frequency with VNS [25,26], which is consequently 
expected to improve a patient’s health-related quality of life and reduce downstream 
medical costs. A wide range of potential scenarios were explored which indicated that 
Ac
ce
pt
ed
 M
an
us
cr
ipt
 
VNS was cost-effective using a £20,000 to £30,000 cost-effectiveness threshold, 
despite the base case holding several conservative assumptions. Future economic 
evaluations would benefit from further research in the relationships between seizure 
frequency, seizure severity, patient and carer HRQoL and, most importantly, 
healthcare resource use.  
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Table 1. Model population characteristics 
Parameter Base-case value Source  
 
Indicated population Adults and children with focal 
seizures, refractory to ASMs and not 
suitable candidates for surgery 
[25,26] 
 
Percentage adults  94.5% Individual patient data 
from E03 and E05 [27] 
Mean starting age 
(years) 
33.2 [25,26] 
Sex (% male) 52.5% [25,26] 
Baseline HRQoL  Varied by age and weighted by 
gender  
[28,29] 
Abbreviations: ASM, anti-seizure medication; HRQoL, health-related quality of life. 
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Table 2. Clinical effectiveness transition probabilities  
  Value sets used for 
DSA 
a
 
Parameter  Base-case transition probability 
value
a
 
Lower 
bound 
b
 
Upper 
bound 
b
 
Short-term (first 3-month 
cycle) health state 
transition probabilities 
(from baseline of ‘no 
response’) [25,26]  
VNS patients: 
<50% (no response): 0.742 
50-74% (responder): 0.166 
75-99% (responder): 0.086 
100% (seizure free): 0.007 
 
ASM only patients: 
<50% (no response): 0.843 
50-74% (responder): 0.138 
75-99% (responder): 0.019 
100% (seizure free): 0.000 
 
0.853 
0.094 
0.049 
0.004 
 
 
0.969 
0.027 
0.004 
0.000 
 
0.630 
0.237 
0.123 
0.009 
 
 
0.716 
0.250 
0.034 
0.000 
Relative increase in 
responders and seizure 
free patients that informed 
long-term health state 
transition probabilities (3-
24 months) for VNS 
patients [32] 
At end of 3 months: 
% responders: 40%  
% seizure free: 2.6% 
 
At end of 24 months: 
% responders: 58%  
% seizure free: 6.5% 
 
 
 
34% 
2.2% 
 
 
49% 
5.5% 
 
46% 
3.0% 
 
 
67% 
7.5% 
Cycle-adjusted 
probabilities applied 
between 3 and 24 
months (derived from 
Englot et al. data) for 
VNS patients 
c
 
 
From <50% (no response) to: 
<50% (no response): 0.954 
50-74% (responder): 0.030 
75-99% (responder): 0.015 
100% (seizure free): 0.001 
 
From 50-74% (responder) to: 
 
0.965 
0.023 
0.011 
0.001 
 
 
 
0.940 
0.039 
0.019 
0.001 
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50-74% (responder): 0.935 
75-99% (responder): 0.052 
100% (seizure free): 0.012 
 
From 75-99% (responder) to: 
75-99% (responder): 0.988 
100% (seizure free): 0.012 
0.935 
0.052 
0.013 
 
0.987 
0.013 
0.935 
0.052 
0.012 
 
0.988 
0.012 
Long-term health state 
transitions for ASM 
patients 
Assumed patients remain in same health state after 3 months 
Abbreviations: ASM, anti-seizure medication; DSA, deterministic sensitivity analysis; VNS, vagus 
nerve stimulation.  
Notes: a, Probabilities have been rounded to three decimal places. The DSA for transition 
probabilities involved setting all transition probabilities simultaneously to the lower bound, or to the 
upper bound.  
b, Upper and lower bounds are based on an assumed +/- 15% difference from the mean, with lower 
bound values selected to give a worse disease response, and upper bound values selected to give 
better disease response.  All transition probabilities are varied simultaneously as a single set.  
c. informed also by assuming that 64%, 33% and 3% of patients who achieve a response from the 
<50% reduction (no response) state over the 3-24 month period would move to the 50-74% 
(responder), 75-99% (responder), and 100% (seizure free) percentage reduction health states, 
respectively. These proportions were derived from the resulting distribution of the responder VNS 
patients at 3 months in the E03 and E05 trials. The estimated transition probabilities were calibrated 
to align with the relative increase in response and seizure freedom calculated from the Englot et al. 
data reported above. 
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Table 3. Proportion of patients experiencing treatment related adverse events 
 Mean  
(range for DSA) 
Parameter Year 1 Year 2 Year 3+ 
Hoarseness 0.29  
(0.243 to 0.335) 
0.19  
(0.134 to 0.246) 
0.02    
(0.000 to 0.049) 
Cough 0.08 
(0.052 to 0.104) 
0.06 
(0.025 to 0.093) 
0.016 
(0.000 to 0.041) 
Dyspnoea 0.08 
(0.053 to 0.107) 
0.03 
(0.006 to 0.054) 
0.03 
(0.000 to 0.065) 
Source: Morris et al 1999 [33]. Abbreviations: DSA, deterministic sensitivity analysis. 
 
 
Table 4. Health state utilities  
Parameter Corresponding seizure 
frequency group reported 
in Messori et al. [22] 
Mean utility 
a 
Range  
for DSA 
0-50% reduction (no response) 10+ per month 0.66 0.65 to 0.67 
50-74% reduction (responder) 2-9 per month 0.79 0.78 to 0.80 
75-99% reduction (responder) 0-1 per month 0.91 0.90 to 0.92 
100% reduction (seizure free) 0 seizures per year 0.96 0.95 to 0.97 
    
Baseline for population 
b
  0.92 
b
 - 
Abbreviations: DSA, deterministic sensitivity analysis. Notes: a, mean values displayed are as reported 
by or derived from the literature. These are used to understand the relative difference between model 
health states; b, this value represents the age- and gender ratio-adjusted baseline for ‘seizure free’ 
patients to which the relative utility differences between health states should be applied. Over the time 
horizon, this baseline utility value was continuously adjusted according to the patients’ mean age. 
 
 
Table 5. VNS adverse events disutilities 
Parameter Mean Upper and lower 
limit for DSA 
a
 
Dyspnoea disutility [40] 0.05 0.043 to 0.058 
Cough disutility [40] 0.046 0.039 to 0.053 
Hoarseness disutility [41] 0.02 0.017 to 0.023 
Abbreviations: DSA,deterministic sensitivity analysis. Notes: 
a, ranges calculated based on an assumed +/- 15% difference 
from the mean.  
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Table 6. Unit costs for health state care items 
Item Activity level Base-case cost* 
[43] 
Range for DSA † 
A&E visits 
a
 
 
20,380,060 £166 £98 to £442 
Non-elective inpatient 
admission: epilepsy 
b
 
191,787 £1,340 £357 to £5,165 
Elective inpatient 
admission: epilepsy
 b
 
4,688 £3,777 - 
 
Day case for epilepsy 
b
 
 
29,667 £587 - 
 
Elective inpatient 
admission for epilepsy, 
incl. day cases [43] 
b
 
Weighted by activity 
level for each HRG 
£1,022 £549 to £7,746 
Neurologist appointment 
[43] 
c
 
 
Adult: 1,223,726 
Child: 30,867 
Mixed: £186 
Adult: £185 
Child: £203 
- 
Adult: £47 to £245 
Child: £72 to £254 
GP visits [42]  £39  
Insertion of 
neurostimulator for 
Treatment of Neurological 
Conditions [43] 
d
 
 
Adult: 876 
Child: 149 
Mixed: £6,987 
Adult: £6,986 
Child: £7006 
- 
Adult: £146 to £7,715 
Child: £5,747 to £12,358 
Abbreviations: A&E, Accident and Emergency; DSA, deterministic sensitivity analysis. GP, general 
practitioner; HRG, healthcare resource group. Notes: *, weighted average for adult and paediatric 
population; †, ranges calculated using either all minimum or all maximum values possible for each HRG 
code; a, HRG codes VB01Z to VB09Z and VB11Z; b, HRG codes AA26C to AA26H which relate to 
people with ‘Muscular, Balance, Cranial or Peripheral Nerve Disorders, Epilepsy or Head Injury’ and is 
weighted accordingly for all comorbidity levels; c, Consultant led for service code 400 and 223; d, HRG 
code AA60A and AA60B. 
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Table 7. Summary of annual health care resource utilisation  
Health care resource 
item 
Health state  
Mean 
(range for DSA) 
100% seizure 
reduction 
(seizure free) 
a
 
75%-99% 
seizure reduction 
[21] 
50-74% seizure 
reduction [34] 
<50% seizure 
reduction [21] 
Mean seizure frequency 
from E03 and E05 
0 243 287 506 
A&E visits 0.00 1.35 
(1.15 to 1.56) 
1.60 
(1.36 to 1.84) 
4.89 
(3.53 to 6.46) 
Inpatient visits 0.00 1.25 
(1.06 to 1.44) 
1.48 
(1.26 to 1.7) 
6.12 
(4.42 to 8.10) 
  Inpatient non-elective 0.00 1.04 
(0.88 to 1.19) 
1.22 
(1.04 to 1.41) 
5.06 
(3.66 to 6.70) 
  Inpatient elective 0.00 0.22 
(0.18 to 0.25) 
0.26 
(0.22 to 0.29) 
1.06 
(0.76 to 1.40) 
Outpatient neurologist 
visits 
1.50  
(1.28 to 1.73)  
7.45 
(6.34 to 8.57) 
8.81 
(7.49 to 10.13) 
16.03 
(11.58 to 21.19) 
GP visits 0.15  
(0.11 to 0.20)  
2.58 
(2.54 to 2.63) 
3.02 
(2.98 to 3.07) 
5.21 
(5.17 to 5.26) 
Abbreviations: A&E, accident and emergency; DSA, deterministic sensitivity analysis; GP, general 
practitioner. Notes: source references for resource use by health state are shown in each column heading. 
a, assumption based on current English clinical guidance [4], which advises that all epilepsy patients 
should have at least one annual review, with an assumed increase in the neurologist frequency to account 
for ASM regimen adjustments. 
 
 
Table 8. Annual costs per health state  
Resource  100% seizure 
reduction 
(seizure free) 
75-99% 
seizure 
reduction 
50-74% seizure 
reduction 
<50% seizure 
reduction 
A&E £0 £225 £266 £811 
Inpatient £0 £1,609 £1,902 £7,866 
Outpatient £279 £1,387 £1,639 £2,981 
GP £6 £101 £119 £205 
Abbreviations: A&E, accident and emergency; GP, general practitioner 
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Table 9. Resource use and costs for VNS 
Parameter 
Cost for 
base case  
Source 
[A] VNS therapy 
device, lead and 
tunneler 
£13,846 Weighted average of Aspire 106 and Sentiva NHS 
supply chain framework price (data on file)  
 [B] VNS therapy 
device 
£11,119 
[C] Implant, explant 
and replacement 
procedure 
Adults and 
children: 
£6,987 
 
NHS Reference cost incorporating: 
 Surgical placement of lead; 
 Placement of electrical pulse generator; 
 Surgical assistance; 
 Anaesthetics; 
 Adverse events associated with procedure; 
 
Weighted by proportion of adults in the cohort. 
 
Adult: £6,986  
Child: £7,006  
[D] Pre- and post-
operative 
neurosurgeon 
review 
Adults and 
children: 
£372 
 
Two outpatient reviews assumed with 
neurosurgeon (service code 150, activities 305,955; 
mixed between consultant and non-consultant led) 
or paediatric neurology (service code 421, activities 
83,770); one preoperatively and one post 
operatively (i.e. programming reviews) 
 
Cost of one adult review = £183    
Cost of one child review: £203  
[E] Clinician training 
Adults and 
children: 
£33 
 
Calculated using the following: 
 Number of clinicians per procedure: 2 
 Cost of 1 hour of clinician time: £109 
(PSSRU 2020) [42] 
 Hours of training per annum required: 7.5 
 Number of VNS procedures undertaken per 
annum: 50 
TOTALS 
 
Implantation = [A+C+D+E] = £ 21,238 
Replacement = [B+C+D+E] = £ 18,511 
Explant = [C+D+E] = £   7,392 
Abbreviations: NHS, National Health Service; VNS, vagus nerve stimulation. 
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Table 10. Costs associated with adverse events 
Adverse event Resources Costs Total-cycle 
adjusted cost for 
a patient 
experiencing a 
given event 
Dyspnoea / Hoarseness / 
Cough 
 
 
1 neurologist visit and GP 
visit per year assumed for 
1-year continuous 
adverse event 
Neurologist: 
£186 [43] 
 
GP:  
£39 [42] 
£56 
 
Abbreviations: GP, general practitioner. 
 
 
Table 11. Base-case cost-effectiveness results 
 VNS + 
ASM 
ASM 
alone 
Increment 
Costs 
Device cost: implant procedure £21,238  £0  £21,238  
Device cost: explantation £126  £0  £126  
Device cost: replacement £7,186  £0  £7,186  
ASM acquisition costs £22,925  £22,925  £0  
TRAE costs £203  £0  £203  
Acute care costs £4,689  £6,090  -£1,401 
Inpatient costs £43,386  £58,176  -£14,790 
Outpatient costs £19,345  £23,220  -£3,874 
Primary care costs £1,344  £1,601  -£258 
Total costs £120,441  £112,011  £8,430  
Health outcomes 
Life years 8.387 8.387 0 
QALYs 6.118 5.642 0.476 
Incremental outcomes 
ICER (per QALY) £17,711  
Incremental net monetary 
benefit (£20,000 threshold) 
£1,089  
Incremental net health benefit 
(£20,000 threshold) 
0.05 
 
Abbreviations: ASM, anti-seizure medication; ICER, incremental cost-effectiveness ratio; 
QALY, quality-adjusted life year; TRAE, treatment-related adverse event; VNS, vagus nerve 
stimulation.  
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Table 12. Deterministic sensitivity analysis 
  Range for DSA ICER 
Parameter or parameter group 
tested 
Base-case 
value 
Low value(s) High value(s) For low 
value(s) 
For high 
value(s) 
Base case    £17,711 
Health state utilities Multiple Lower limits  Upper limits  £17,409 £18,300 
TRAE probabilities Multiple Lower limits  Upper limits  £16,985 £18,621 
TRAE disutilities Multiple Lower limits for all 
TRAEs 
Upper limits for all 
TRAEs 
£17,553 £17,872 
Health state transition probabilities 
for VNS and ASM only arms 
Multiple Lower limits for all 
transitions 
Upper limits for all 
transitions 
£9,816 £26,059 
Long-term health state transition 
probabilities 
Multiple Lower limits Upper Limits £25,211 £10,932 
Mortality: SMR 2.2 1.97 2.47 £17,667 £17,763 
VNS battery replacement 
probabilities 
Extrapolation 
function 
Lower limits for 
extrapolation 
coefficients 
Upper limits for 
extrapolation 
coefficients 
£17,464 £17,944 
VNS explantation probabilities Extrapolation 
function 
Lower limits for 
extrapolation 
coefficients 
Upper limits for 
extrapolation 
coefficients 
£16,726 £49,623 
ASM reduction with VNS, as ratio 
compared to ASMs only 
1.0 0.85 1.15 £13,450 £21,973 
Inpatient admission unit costs Multiple Minimum values  
for each HRG 
Maximum values  
for each HRG 
£39,357 VNS DOM 
Outpatient consultant visit unit cost  £186 £49 £245 £22,650 £15,581 
A&E unit cost £166 £98 £442 £18,922 £12,818 
VNS procedure unit costs £6,987 £454 £7,971 VNS DOM £20,614 
Inpatient resource use Multiple Lower limits Upper limits £27,248 £6,454 
Outpatient/GP resource use Multiple Lower limits Upper limits £20,780 £13,990 
A&E resource use Multiple Lower limits Upper limits £18,656 £16,589 
VNS device cost £11,119 £9,451 £12,786 £11,988 £23,435 
VNS training cost £33 £28 £38 £17,674 £17,762 
Implant cost £21,238 £18,052 £24,423 £11,018 £24,404 
Explant cost £7,392 £6,283 £8,501 £17,671 £17,751 
Replacement cost £18,511 £15,734 £21,287 £15,447 £19,976 
Abbreviations: A&E, hospital accident & emergency department; ASM, anti-seizure medication; DSA, 
deterministic sensitivity analysis; GP, general practitioner; HRG, healthcare resource group code; ICER, 
incremental cost-effectiveness ratio; QALY, quality adjusted life year; SMR, standardized mortality ratio; 
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TRAE, treatment-related adverse event; VNS, vagus nerve stimulation; VNS DOM, VNS+ASM treatment 
dominates ASM only treatment. 
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